Release Date: 2024-06-12

Immunotherapy in Breast Cancer

Baran Akagunduz (Author), Mehmet Cihan Icli (Author)

Release Date: 2024-06-12

Breast cancer is the most common cancer in women and a multidisciplinary approach has reduced breast cancer mortality. Early stage and locally advanced breast cancers require systemic therapy to reduce recurrence and relapse. Pathologic complete response (pCR) has been one of the main targets of neoadjuvant systemic therapy. With the advent of immune checkpoint inhibitors [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page187
    Last Page204
    DOIhttps://doi.org/10.69860/nobel.9786053359388.13
    Page Count18
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Breast cancer is the most common cancer in women and a multidisciplinary approach has reduced breast cancer mortality. Early stage and locally advanced breast cancers require systemic therapy to reduce recurrence and relapse. Pathologic complete response (pCR) has been one of the main targets of neoadjuvant systemic therapy. With the advent of immune checkpoint inhibitors (ICIs), Immunotherapy has revolutionized the treatment of solid tumors. Immunotherapy in breast cancer has been used especially in the immunogenic subtype of TNBC (triple-negative breast cancer), which has higher levels of TIL (tumor-infiltrating lymphocytes). The KEYNOTE-522 study showed that adding pembrolizumab to neoadjuvant chemotherapy increased pCR rates in patients with early-stage TNBC. The IMPASSION031 study also showed that the combination of atezolizumab and nab-paclitaxel increased the pCR rate from 41% to 58%. In the KEYNOTE-355 study, the addition of pembrolizumab to chemotherapy in patients with TNBC with a combined positive score (CPS) ≥10 significantly improved progression-free and overall survival. Current studies are investigating various combinations of chemotherapy and immunotherapy, as well as new immunotherapeutic agents in combination with tumor vaccines, oncolytic viruses and adaptive cellular therapy.

    Baran Akagunduz (Author)
    MD, Associate Professor, Bahrain Oncology Center
    https://orcid.org/0000-0002-4979-3123
    3EDUCATION 2003-2009: İstanbul University School Of Medicine 2009-2014: İstanbul Research and Education Hospital Internal Medicine 2009-2014: Dokuz Eylul University School of Medicine Medical Oncology CLINICAL EXPERIENCE 2009-2014 Resident Internal Medicine Istanbul Research and Education Hospital 2014-2016 Specialist İnternal Medicine Tunceli State Hospital 2016-2019 Fellow Medical Oncology Dokuz Eylul University School of Medicine 2019-Present Specialist Medical Oncology Erzincan Mengucek Gazi Research Hospital

    Mehmet Cihan Icli (Author)
    MD, Assistant Professor, Hacettepe University
    https://orcid.org/0000-0002-7857-6902
    32014 Gaziantep University Faculty of Medicine Gaziantep University 2016-2018 Department of Internal Medicine Balıkesir University Faculty of Medicine 2018-2020 Department of Internal Medicine Harran University Faculty of Medicine 2023- Department of Medical Oncology Hacettepe University Faculty of Medicine

    • Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.

    • . https://gco.iarc.fr/today/en/fact-sheets-populations#countries.

    • Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ 2012; 344:e2718.

    • Caswell-Jin JL, Sun LP, Munoz D, et al. Analysis of Breast Cancer Mortality in the US1975 to 2019. JAMA 2024; 331:233.

    • Hortobagyi GN, Connolly JL, D’Orsi CJ, Yang WT. Breast. In: Amin MB, Edge S, Greene F, et al., eds; American Joint Committee on Cancer. AJCC cancer staging manual, 8th ed. Springer, 2017:589–636.

    • Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:290–303.

    • Taylor C, McGale P, Probert J, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ 2023; 381:e074684.

    • Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020; 38:203.

    • Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167:671.

    • Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375.

    • Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559.

    • Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:1721

    • Fujiwara Y, Horita N, Adib E, et al. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol 2024; 25:62.

    • Park HJ, Kim KW, Won SE, et al. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4:e211136

    • Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020; 396:1090.

    • Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279

    • Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556– 67. Major phase III randomised controlled trial showing improved EFS from neoadjuvant ICI, with carboplatin. [PubMed]

    • Pusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent RA, McArthur HL, et al. Eventfree survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. Journal of Clinical Oncology. 2022;40(16_suppl):503-. Demonstrates the extent of residual disease post neoadjuvant chemo-ICI is linked to EFS benefit from ICI).

    • Loibl S, Loirat D, Tolaney SM, et al: Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer 178:23-33, 2023.

    • D’Abreo N, Adams S: Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first? Nat Rev Clin Oncol 2019, 16(7):399–400.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!